Daniel T. Starczynowski, Ph.D. - Publications

Affiliations: 
2006 Boston University, Boston, MA, United States 
Area:
Molecular Biology

83 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, ... ... Starczynowski DT, et al. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 14: eabb7695. PMID 35263148 DOI: 10.1126/scitranslmed.abb7695  0.3
2022 Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, ... ... Starczynowski DT, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. PMID 35045331 DOI: 10.1016/j.stem.2021.12.007  0.343
2021 Niederkorn M, Ishikawa C, M Hueneman K, Bartram J, Stepanchick E, R Bennett J, E Culver-Cochran A, Bolanos LC, Uible E, Choi K, Wunderlich M, Perentesis JP, M Chlon T, Filippi MD, Starczynowski DT. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. PMID 34465865 DOI: 10.1038/s41375-021-01394-z  0.337
2020 Schieber M, Marinaccio C, Bolanos LC, Haffey WD, Greis KD, Starczynowski DT, Crispino JD. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal. 10: 98. PMID 33024076 DOI: 10.1038/s41408-020-00362-7  0.327
2020 Niederkorn M, Agarwal P, Starczynowski DT. TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology. PMID 32910997 DOI: 10.1016/J.Exphem.2020.08.010  0.384
2020 Muto T, Walker CS, Choi K, Hueneman K, Smith MA, Gul Z, Garcia-Manero G, Ma A, Zheng Y, Starczynowski DT. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. PMID 32313245 DOI: 10.1038/S41590-020-0663-Z  0.425
2020 Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, ... ... Starczynowski DT, et al. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. PMID 32149729 DOI: 10.1172/Jci127907  0.331
2020 Niederkorn M, Hueneman K, Choi K, Varney ME, Romano L, Pujato MA, Greis KD, Inoue JI, Meetei R, Starczynowski DT. TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports. 30: 2776-2790.e6. PMID 32101751 DOI: 10.1016/J.Celrep.2020.01.093  0.416
2019 Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, ... ... Starczynowski DT, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 11. PMID 31484791 DOI: 10.1126/scitranslmed.aaw8828  0.35
2019 Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, ... ... Starczynowski DT, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology. PMID 31011167 DOI: 10.1038/S41556-019-0314-5  0.459
2019 Rawat R, Starczynowski DT, Ntziachristos P. Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease. Current Opinion in Cell Biology. 58: 85-94. PMID 30897496 DOI: 10.1016/J.Ceb.2019.02.008  0.317
2019 Chlon TM, Stepanchick E, Choi K, Zheng Y, Hueneman K, Davis A, Starczynowski DT. The Inherited MDS Gene DDX41 Is Required for Ribosome Biogenesis and Cell Viability Blood. 134: 773-773. DOI: 10.1182/Blood-2019-127471  0.455
2019 Barreyro L, Sampson A, Hueneman K, Choi K, Christie S, Wang D, Huang G, Starczynowski DT. Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia Blood. 134: 2983-2983. DOI: 10.1182/Blood-2019-127307  0.374
2019 Goll JB, Lindsley RC, Hooper WF, Bejar R, Walker J, Fulton R, Abel GA, Al Baghdadi T, Deeg HJ, DeZern AE, Ebert B, Epling-Burnette P, Foran JM, Gorak EJ, Gore SD, ... ... Starczynowski DT, et al. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study Blood. 134: 4271-4271. DOI: 10.1182/Blood-2019-126978  0.314
2019 Choudhary GS, Smith MA, Pellagatti A, Bhagat TD, Gordon S, Pandey S, Shah N, Aluri S, Booher RN, Ramachandra M, Samson ME, Pradhan K, Bowman TV, Pillai MM, Guha C, ... ... Starczynowski DT, et al. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML Blood. 134: 4224-4224. DOI: 10.1182/Blood-2019-124458  0.45
2019 Muto T, Guillamot M, Fang J, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee L, Greis KD, Khodadadi-Jamayran A, Lujambio A, Lowe SW, ... ... Starczynowski DT, et al. Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity Blood. 134: 727-727. DOI: 10.1182/Blood-2019-121423  0.503
2019 Bal S, Girnius S, Starczynowski D, Landau H, Choi K. Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase Biology of Blood and Marrow Transplantation. 25: S383-S384. DOI: 10.1182/Blood-2018-99-115523  0.348
2018 Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances. 2: 2491-2504. PMID 30275007 DOI: 10.1182/Bloodadvances.2018024166  0.402
2018 Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. PMID 30104218 DOI: 10.1182/Blood-2018-03-784116  0.312
2018 Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, ... Starczynowski DT, et al. TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis. Cell Reports. 22: 1250-1262. PMID 29386112 DOI: 10.1016/J.Celrep.2018.01.013  0.437
2018 Barreyro L, Sampson A, Hueneman K, Bolanos LC, Pujato M, Chutipongtanate S, Wyder M, Haffey W, Choi K, Neelamraju Y, Smith MA, Niederkorn M, Ramesh V, Muto T, O'Brien E, ... ... Starczynowski DT, et al. Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies Blood. 132: 4050-4050. DOI: 10.1182/Blood-2018-99-115359  0.442
2018 Starczynowski DT. Chronic Innate Immune Signaling in Myelodysplasia Blood. 132: SCI-33-SCI-33. DOI: 10.1182/Blood-2018-99-109492  0.35
2017 Kong F, Liu Z, Jain VG, Shima K, Suzuki T, Muglia LJ, Starczynowski DT, Pasare C, Bhattacharyya S. Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages. Journal of Immunology (Baltimore, Md. : 1950). PMID 29038250 DOI: 10.4049/Jimmunol.1700443  0.344
2017 Niederkorn M, Starczynowski DT. GMP-ing to Spatial Conclusions about Emergency and Leukemic Myelopoiesis. Cell Stem Cell. 20: 579-581. PMID 28475879 DOI: 10.1016/J.Stem.2017.04.005  0.322
2017 Smith MA, Choudhary G, Pellagatti A, Choi K, Bhagat TD, Salomonis N, Walter MJ, Komurov K, Sampson MES, Gordon S, Ahrens DV, Pradhan K, Steidl UG, Booher R, Boultwood J, ... ... Starczynowski D, et al. Splicesome Mutant MDS and AML Cells Activate Innate Immune Signaling By Regulating the Expression of Therapeutically Targetable IRAK4 Isoforms Blood. 130: 785-785. DOI: 10.1182/Blood.V130.Suppl_1.785.785  0.396
2016 Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, ... ... Starczynowski DT, et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology. PMID 28024152 DOI: 10.1038/Ni.3654  0.389
2016 Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, ... ... Starczynowski DT, et al. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leukemia Research. 50: 85-94. PMID 27697661 DOI: 10.1016/J.Leukres.2016.09.018  0.388
2016 Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Grimes HL, Fontanillo C, Komurov K, MacBeth K, Starczynowski DT. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine. PMID 27294874 DOI: 10.1038/Nm.4127  0.359
2016 Barreyro L, Sampson AM, Bolanos L, Niederkorn M, Pujato M, Smith MA, Tomoya M, Haffey WD, Christie S, Liu X, Weirauch M, Greis K, Seibel WL, Starczynowski DT. Inhibition of UBE2N As a Therapeutic Approach in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 128: 579-579. DOI: 10.1182/Blood.V128.22.579.579  0.457
2016 Fang J, Bolanos L, Serrano-Lopez J, Christie S, Cancelas JA, Starczynowski DT. TRAF6 Is Essential for Maintaining Hematopoietic Stem Cell Homeostasis Blood. 128: 568-568. DOI: 10.1182/Blood.V128.22.568.568  0.427
2016 Melgar K, Walker M, Jiang J, Wison K, Choi K, Mulloy JC, Thomas CJ, Starczynowski DT. Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML Blood. 128: 36-36. DOI: 10.1182/Blood.V128.22.36.36  0.345
2016 Smith MA, Choi K, Salomonis N, Walter MJ, Komurov K, Starczynowski DT. Alternative Splice Variants of IRAK4 That Activate Innate Immune Signaling Are Associated with U2AF1 Mutations in Myelodysplastic Syndrome and Acute Myeloid Leukemia Blood. 128: 1531-1531. DOI: 10.1182/Blood.V128.22.1531.1531  0.426
2016 Niederkorn M, Varney M, Smith MA, Meetei RA, Starczynowski DT. Tifab, a Del(5q) MDS/AML Gene, Regulates USP15 Activity and p53 Blood. 128: 1130-1130. DOI: 10.1182/Blood.V128.22.1130.1130  0.448
2015 Fang J, Starczynowski DT. Genomic instability establishes dependencies on acquired gene regulatory networks: A novel role of p62 in myeloid malignancies with del(5q). Molecular & Cellular Oncology. 2: e1014219. PMID 27308507 DOI: 10.1080/23723556.2015.1014219  0.408
2015 Adams AK, Bolanos LC, Dexheimer PJ, Karns RA, Aronow BJ, Komurov K, Jegga AG, Casper KA, Patil YJ, Wilson KM, Starczynowski DT, Wells SI. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Oncotarget. PMID 26527316 DOI: 10.18632/Oncotarget.6028  0.402
2015 Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski JP, Meetei RA, Inoue J, ... Starczynowski DT, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. The Journal of Experimental Medicine. 212: 1967-85. PMID 26458771 DOI: 10.1084/Jem.20141898  0.443
2015 Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, et al. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology. 43: 858-868.e7. PMID 26163797 DOI: 10.1016/J.Exphem.2015.05.018  0.311
2015 Varney ME, Melgar K, Niederkorn M, Smith M, Barreyro L, Starczynowski DT. Deconstructing innate immune signaling in Myelodysplastic Syndromes. Experimental Hematology. PMID 26143580 DOI: 10.1016/J.Exphem.2015.05.016  0.374
2015 Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 29: 1458-69. PMID 25761935 DOI: 10.1038/Leu.2015.69  0.383
2015 Rhyasen GW, Starczynowski DT. IRAK signalling in cancer British Journal of Cancer. 112: 232-237. PMID 25290089 DOI: 10.1038/Bjc.2014.513  0.356
2015 Serrano-Lopez J, Serrano J, Zhang C, Wellendorf A, Fang J, Sanchez-Garcia J, Grimes HL, Starczynowski DT, Cancelas JA. Systemic Inflammation Recruits Ccr7+ Dendritric-Biased Granulocyte-Macrophage Progenitors to Lymphatic Circulation in a Non-Canonical Traf6-Dependent Manner Blood. 126: 785-785. DOI: 10.1182/Blood.V126.23.785.785  0.409
2015 Melgar K, Walker M, Jiang J, Wilson K, Mulloy JC, Thomas CJ, Starczynowski DT. Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML Blood. 126: 3690-3690. DOI: 10.1182/Blood.V126.23.3690.3690  0.335
2015 Fang J, Bolanos L, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Greis K, Stoilov P, Filippi M, Maciejewski JP, Garcia-Manero G, Weirauch M, Salomonis N, Geiger H, ... ... Starczynowski D, et al. Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia Blood. 126: 143-143. DOI: 10.1182/Blood.V126.23.143.143  0.445
2014 Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, Wellendorf AM, Hill SE, Watkins M, Gonzalez-Nieto D, Aronow BJ, Starczynowski DT, Civitelli R, Diaz-Meco MT, Moscat J, et al. p62 is required for stem cell/progenitor retention through inhibition of IKK/NF-κB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Reports. 9: 2084-97. PMID 25533346 DOI: 10.1016/J.Celrep.2014.11.031  0.404
2014 Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network. Cell Reports. 8: 1328-38. PMID 25199827 DOI: 10.1016/J.Celrep.2014.07.062  0.404
2014 Starczynowski DT. Errant innate immune signaling in del(5q) MDS. Blood. 124: 669-71. PMID 25082861 DOI: 10.1182/Blood-2014-06-581728  0.307
2014 Zhao JL, Starczynowski DT. Role of microRNA-146a in normal and malignant hematopoietic stem cell function. Frontiers in Genetics. 5: 219. PMID 25071842 DOI: 10.3389/Fgene.2014.00219  0.312
2014 Beverly LJ, Starczynowski DT. IRAK1: oncotarget in MDS and AML. Oncotarget. 5: 1699-700. PMID 24880611 DOI: 10.18632/Oncotarget.1880  0.474
2014 Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line Leukemia. 28: 1142-1145. PMID 24326684 DOI: 10.1038/Leu.2013.372  0.388
2014 Chang K, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt R, Wellendorf A, Hill S, Watkins M, Civitelli R, Starczynowski DT, Diaz-Meco MT, Moscat J, Cancelas JA. Sqstm1 Is Required to Retain Hematopoietic Stem Cell/ Progenitors As a Negative Regulator of Macrophage-Dependent Inflammatory Signaling in the Bone Marrow Osteoblastic Niche Blood. 124: 350-350. DOI: 10.1182/Blood.V124.21.350.350  0.421
2014 Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, MacBeth KJ, Komurov K, Starczynowski DT. A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes Blood. 124: 1898-1898. DOI: 10.1182/Blood.V124.21.1898.1898  0.365
2013 Rhyasen GW, Bolanos L, Starczynowski DT. Differential IRAK signaling in hematologic malignancies. Experimental Hematology. 41: 1005-7. PMID 24084080 DOI: 10.1016/J.Exphem.2013.09.008  0.528
2013 Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, ... ... Starczynowski DT, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 24: 90-104. PMID 23845443 DOI: 10.1016/J.Ccr.2013.05.006  0.411
2013 Guo F, Zhang S, Grogg M, Cancelas JA, Varney ME, Starczynowski DT, Du W, Yang JQ, Liu W, Thomas G, Kozma S, Pang Q, Zheng Y. Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis. Haematologica. 98: 1353-8. PMID 23716557 DOI: 10.3324/Haematol.2012.080424  0.404
2013 Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Rao DS, Mulloy JC, Maciejewski JP, Cancelas JA, Starczynowski DT. SQSTM1/p62 Is a Necessary Cofactor In MDS/AML With Deletion Of Mir-146a Blood. 122: 747-747. DOI: 10.1182/Blood.V122.21.747.747  0.405
2013 Varney M, Christie S, Niederkorn M, Fang J, Jerez A, Maciejewski JP, Inoue J, Starczynowski DT. Deletion Of Tifab, a Novel Candidate Gene On Chromosome 5q, Results In Hematopoietic Defects By Changing The Dynamic Range Of Innate Immune Pathway Activation Blood. 122: 102-102. DOI: 10.1182/Blood.V122.21.102.102  0.404
2013 Fang J, Liu X, Barker B, Bolanos L, Wei Y, Manero GG, Starczynowski DT. Disease-Relevant Expression Of TRAF6 In Mouse HSC Results In An MDS-Like Disease Blood. 122: 101-101. DOI: 10.1182/Blood.V122.21.101.101  0.413
2012 Vercauteren SM, Starczynowski DT, Sung S, McNeil K, Salski C, Jensen CL, Bruyere H, Lam WL, Karsan A. T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone. British Journal of Haematology. 156: 409-12. PMID 25289412 DOI: 10.1182/Blood.V118.21.2808.2808  0.314
2012 Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 120: 858-67. PMID 22685174 DOI: 10.1182/Blood-2012-02-407999  0.43
2012 Fang J, Varney M, Starczynowski DT. Implication of microRNAs in the pathogenesis of MDS. Current Pharmaceutical Design. 18: 3170-9. PMID 22571695 DOI: 10.2174/1381612811209023170  0.305
2012 Fang J, Jerez A, Rasch C, Bolanos L, Maciejewski JP, Starczynowski DT. Haploinsufficiency of Mir-146a in High-Risk Del(5q) MDS/AML Requires an Intrachromosomal Gene Network Involving p62/TRAF6/NF-κB Blood. 120: 557-557. DOI: 10.1182/Blood.V120.21.557.557  0.378
2012 Ibrahim R, Woltosz JJW, Starczynowski DT, Umlandt P, Karsan A. Enforced Expression of the Toll/Interleukin-1 Receptor Associated Protein in Murine Marrow Results in MDS-Like Bone Marrow Failure Mediated by Interferon Gamma Blood. 120: 555-555. DOI: 10.1182/Blood.V120.21.555.555  0.353
2012 Rhyasen G, Wunderlich M, Mulloy JC, Starczynowski DT. Development and Characterization of a Novel Human Xenograft Model Using an MDS Patient-Derived Cell Line Blood. 120: 3814-3814. DOI: 10.1182/Blood.V120.21.3814.3814  0.398
2012 Varney M, Jerez A, Fang J, Miller D, Bolanos L, Karsan A, Maciejewski JP, Starczynowski DT. Tifab, a Novel Candidate Gene in Deletion Chromosome 5q, Contributes to Deregulation of NF-κB Signaling in MDS/AML. Blood. 120: 2812-2812. DOI: 10.1182/Blood.V120.21.2812.2812  0.455
2011 Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. The Journal of Clinical Investigation. 121: 4095-105. PMID 21911935 DOI: 10.1172/Jci58818  0.35
2011 Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival. Experimental Hematology. 39: 167-178.e4. PMID 20933052 DOI: 10.1016/J.Exphem.2010.09.011  0.338
2011 Rhyasen G, Bolanos L, Fang J, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Starczynowski DT. Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 118: 612-612. DOI: 10.1182/Blood.V118.21.612.612  0.478
2011 Fang J, Bolanos L, Rhyasen G, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Starczynowski DT. Degradation of TRAF6 by Bortezomib-Induced Autophagy Contributes to Cell Death in Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood. 118: 2452-2452. DOI: 10.1182/Blood.V118.21.2452.2452  0.478
2010 Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, Tsang P, Leitch H, Karsan A. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. American Journal of Clinical Pathology. 134: 119-26. PMID 20551276 DOI: 10.1309/Ajcph27Zizejlorf  0.307
2010 Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematology/Oncology Clinics of North America. 24: 343-59. PMID 20359630 DOI: 10.1016/J.Hoc.2010.02.008  0.335
2010 Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle (Georgetown, Tex.). 9: 855-6. PMID 20160505 DOI: 10.4161/Cc.9.5.11156  0.302
2010 Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature Medicine. 16: 49-58. PMID 19898489 DOI: 10.1038/Nm.2054  0.345
2008 Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 112: 3412-24. PMID 18663149 DOI: 10.1182/Blood-2007-11-122028  0.317
2008 Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi AL, Hirst M, Hogge DE, Marra M, Wells RA, Lam W, Humphries RK, Karsan A. Identification of Mir-145 and Mir-146a as Micrornas Involved in the Pathogenesis of 5q- Syndrome Blood. 112: 853-853. DOI: 10.1182/Blood.V112.11.853.853  0.327
2007 Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, Leeman JR, Siebert R, Gilmore TD. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene. 26: 2685-94. PMID 17072339 DOI: 10.1038/Sj.Onc.1210089  0.769
2007 Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A, Spinelli JJ, Eaves CJ, Eaves AC, Horsman DE, Lam WL, Karsan A. High-Resolution CGH Analysis of CD34+ Cells from Lower-Risk Myelodysplastic Patients Reveals Cryptic Copy Number Alterations and Predicts Overall and Leukemia-Free Survival. Blood. 110: 2431-2431. DOI: 10.1182/Blood.V110.11.2431.2431  0.343
2005 Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 24: 7355-68. PMID 16027730 DOI: 10.1038/Sj.Onc.1208902  0.645
2005 Trautmann H, Starczynowski DT, Pott C, Harder L, Arnold N, Siebert R, Kneba M, Gilmore TD. An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances REL’s In Vitro Transforming Activity. Blood. 106: 2617-2617. DOI: 10.1182/Blood.V106.11.2617.2617  0.69
2004 Kalaitzidis D, Ok J, Sulak L, Starczynowski DT, Gilmore TD. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene. 23: 7580-7. PMID 15326488 DOI: 10.1038/Sj.Onc.1207912  0.741
2004 Gilmore TD, Starczynowski DT, Kalaitzidis D. RELevant gene amplification in B-cell lymphomas? Blood. 103: 3243-4; author reply. PMID 15070712 DOI: 10.1182/Blood-2003-11-4019  0.758
2004 Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 23: 2275-86. PMID 14755244 DOI: 10.1038/Sj.Onc.1207410  0.757
2003 Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene. 22: 6928-36. PMID 14534540 DOI: 10.1038/Sj.Onc.1206801  0.653
2002 Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Letters. 181: 1-9. PMID 12430173 DOI: 10.1016/S0304-3835(01)00795-9  0.756
Show low-probability matches.